Figures
During the preparation of Fig 1C in this article [1], the underlying data for panel 3CI were inadvertently used to represent the data in panel 3CIV. In the updated Fig 1 below, the correct panel has been included for Fig 3CIV. Underlying data provided for the corrected Fig 1 are in S1 File. All raw data underlying the remainder of the results reported in the article are available from the first author.
(A) Representative figure of myocyte cross-section (HE stain, x400); (B) statistic results of myocyte cross-section area; (C) representative figure of myocardial fibrosis (Masson’s stain, x100); (D) statistic results of myocardial fibrosis; (E) representative figure of perivascular fibrosis (Masson’s stain, x100); (F) statistic results of perivascular fibrosis; (G) hydroxyproline content in cardiac tissue. I: Sham group; II: Model group; III: MHBFC 6 mg kg-1 group; IV: MHBFC 12 mg kg-1 group; V: Lisinopril 15 mg kg-1 group. The myocyte cross-sectional area, levels of myocardial and perivascular fibrosis, and the hydroxyproline content all increased significantly when compared with the sham-operated rats. MHBFC at dose of 12 mg/kg for 6 weeks could reverse all these pathological changes in LVH parameters, and MHBFC at dose of 6 mg/kg for 6 weeks could reduce the myocyte cross-sectional area and level of myocardial fibrosis. The data are expressed as the mean±SD, n = 6. #P<0.05, ##P<0.01 vs. Sham group; *P<0.05, **P<0.01 vs. Model group.
Supporting information
S1 File. Underlying data supporting Fig 1A–1G.
https://doi.org/10.1371/journal.pone.0276104.s001
(ZIP)
Reference
- 1. Huang J, Tang X, Liang X, Wen Q, Zhang S, Xuan F, et al. (2014) The Effects of 17-Methoxyl-7-Hydroxy-Benzene-Furanchalcone on the Pressure Overload-Induced Progression of Cardiac Hypertrophy to Cardiac Failure. PLoS ONE 9(3): e91834. https://doi.org/10.1371/journal.pone.0091834. pmid:24622486
Citation: Huang J, Tang X, Liang X, Wen Q, Zhang S, Xuan F, et al. (2022) Correction: The Effects of 17-Methoxyl-7-Hydroxy-Benzene-Furanchalcone on the Pressure Overload-Induced Progression of Cardiac Hypertrophy to Cardiac Failure. PLoS ONE 17(10): e0276104. https://doi.org/10.1371/journal.pone.0276104
Published: October 12, 2022
Copyright: © 2022 Huang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.